智通财经APP获悉，宜明昂科-B(01541)涨超6%，截至发稿，涨6.13%，报6.41港元，成交额374.06万港元。
消息面上，5月7日，宜明昂科宣布，就其2024年8月1日与Instil Bio, Inc对IMM2510及IMM27M达成的授权及合作，鉴于临床合作开发的顺利且快速的推进，已如期收到第二笔近期付款500万美元。随着第二笔近期付款500万美元顺利到账，该项目累计收款金额已高达2000万美元。
目前，IMM2510已完成一项用于晚期实体瘤的剂量递增临床试验，并显示出多项疗效信号，其中包括对PD-1抑制剂治疗失败的鳞状非小细胞肺癌患者的显著疗效；另外，IMM2510与化疗联用一线治疗非小细胞肺癌患者的II期临床研究、IMM2510与IMM27M联合治疗晚期实体瘤的临床研究均已开始入组。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.